Table 1.
Experimental Gene Therapy of Neurological Disorders Using HSV Vectors
| Pathological Disturbances/Clinical Indications | Therapeutic Transgenes | Stage | Ref. |
|---|---|---|---|
| Replication-Defective Vectors | |||
| Epilepsy | FGF-2, BDNF | Preclinical | [35] |
| Multiple sclerosis | IL-4, IL-1ra | Preclinical | [34, 48, 49] |
| Alzheimer’s disease | shRNA, neprilysin | Preclinical | [36] |
| Parkinson’s disease | GDNF bcl-2 Erithropoietin | Preclinical | [51, 52] [50, 51] [37] |
| Diabetes | Neurotrophic factors | Preclinical | [56-60] |
| Chronic pain | Preproenkephalin | Phase I | [38, 39, 88] |
| Lysosomal storage diseases: Tay-Sachs | HexA α subunit | Preclinical | [42] |
| Replication-Competent Vectors | |||
| Lysosomal disorders: MPS VII | β-glucoronidase | Preclinical | [41] |
| Multiple sclerosis | IL-4, IL-10 | Preclinical | [76] |
| Ischemic brain injury | HSV-2 ICP0PK | Preclinical | [77] |
| Chronic pain | Preproenkephalin | Preclinical | [69, 70] |